{"id":"moxifloxacin-topical","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival irritation"},{"rate":null,"effect":"Eye discomfort or pain"},{"rate":null,"effect":"Ocular redness"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This dual inhibition leads to rapid bactericidal activity against a wide range of gram-positive and gram-negative bacteria, as well as atypical organisms. When applied topically to the eye, it achieves high local concentrations to treat ocular infections.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:57.414Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis (topical ophthalmic)"},{"name":"Bacterial corneal ulcer (topical ophthalmic)"},{"name":"Other ocular bacterial infections (topical ophthalmic)"}]},"trialDetails":[{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT07308938","phase":"PHASE2","title":"Fluorometholone Study","status":"NOT_YET_RECRUITING","sponsor":"Vishal Jhanji","startDate":"2026-03-31","conditions":"Keratitis Bacterial, Corneal Ulcer (Diagnosis)","enrollment":174},{"nctId":"NCT05110001","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-08-03","conditions":"Acanthamoeba Keratitis, Fungal Keratitis","enrollment":330},{"nctId":"NCT06271772","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-07-01","conditions":"Bacterial Keratitis","enrollment":60},{"nctId":"NCT07276802","phase":"PHASE4","title":"The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Research Insight LLC","startDate":"2025-12-05","conditions":"Post Cataract Surgery","enrollment":40},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06363292","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2024-01-30","conditions":"Ophthalmological Agent Toxicity, Bacterial Conjunctivitis","enrollment":37},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT04750655","phase":"PHASE4","title":"Antibiotic Resistance In Eye Surgeries","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-03-01","conditions":"Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome","enrollment":108},{"nctId":"NCT06163105","phase":"NA","title":"The Effect of Gland Expression on the Regeneration of Meibomian Gland","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-10-03","conditions":"Meibomian Gland Dysfunction","enrollment":64},{"nctId":"NCT06879301","phase":"EARLY_PHASE1","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-10-19","conditions":"Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation","enrollment":60},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT04204122","phase":"PHASE2","title":"Vigamox Treatment for Ocular Graft-Versus-Host Disease","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2020-06-15","conditions":"Ocular Graft-versus-host Disease","enrollment":""},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT05881187","phase":"NA","title":"Pack Cross Linking for Infectious Keratitis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-06-15","conditions":"Infectoius Keratitis","enrollment":60},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT05162625","phase":"PHASE2","title":"Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2021-12-10","conditions":"Endophthalmitis, Open Globe Injury, Moxifloxacin","enrollment":100},{"nctId":"NCT05079854","phase":"PHASE4","title":"Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis","status":"UNKNOWN","sponsor":"Federal University of São Paulo","startDate":"2021-10-01","conditions":"Endophthalmitis, Trauma, Corneal","enrollment":100},{"nctId":"NCT03640650","phase":"PHASE4","title":"Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.","status":"TERMINATED","sponsor":"PeriPharm","startDate":"2018-08-15","conditions":"Cataract Surgery","enrollment":80},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":"Cataract","enrollment":31},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT04212429","phase":"PHASE1, PHASE2","title":"The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis Postoperative","enrollment":128},{"nctId":"NCT04214821","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis","enrollment":128},{"nctId":"NCT04457063","phase":"PHASE2, PHASE3","title":"Endothelial Cell Loss After Penetrating Keratoplasty","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2018-07-01","conditions":"Keratoconus","enrollment":8},{"nctId":"NCT04205916","phase":"PHASE4","title":"A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery","status":"RECRUITING","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2019-11-04","conditions":"Patient Preference","enrollment":50},{"nctId":"NCT00690313","phase":"PHASE4","title":"Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections","status":"COMPLETED","sponsor":"Illinois Retina Associates","startDate":"2008-08","conditions":"Intravitreal Injection Patients","enrollment":22},{"nctId":"NCT01097447","phase":"","title":"Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)","status":"TERMINATED","sponsor":"Cxlusa","startDate":"2009-12-01","conditions":"Keratoconus, Ectasia, Degeneration","enrollment":2619},{"nctId":"NCT00324168","phase":"PHASE4","title":"Steroids for Corneal Ulcers Trial","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2006-09","conditions":"Corneal Ulcer, Eye Infections, Bacterial","enrollment":500},{"nctId":"NCT02865876","phase":"PHASE3","title":"Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis","status":"UNKNOWN","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2015-06","conditions":"Keratitis","enrollment":264},{"nctId":"NCT02816905","phase":"PHASE4","title":"Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-10","conditions":"Intraocular Pressure","enrollment":40},{"nctId":"NCT00831961","phase":"","title":"Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2009-01","conditions":"Age-related Macular Degeneration","enrollment":24},{"nctId":"NCT02625467","phase":"PHASE1","title":"Treatment of Keratoconus With PALK Versus PK","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2013-06","conditions":"Keratoconus","enrollment":28},{"nctId":"NCT01928693","phase":"PHASE2","title":"A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.","status":"TERMINATED","sponsor":"Cornea Consultants Of Nashville","startDate":"2013-07","conditions":"Corneal Ulcers","enrollment":2},{"nctId":"NCT01546402","phase":"PHASE4","title":"Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-05","conditions":"Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema","enrollment":20},{"nctId":"NCT01515826","phase":"PHASE3","title":"VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2014-03","conditions":"Cataracts","enrollment":""},{"nctId":"NCT01071902","phase":"PHASE3","title":"Safety and Efficacy of Moxidex Otic","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2010-02","conditions":"Acute Otitis Media","enrollment":400},{"nctId":"NCT00578773","phase":"PHASE2","title":"A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-11","conditions":"Acute Otitis Media","enrollment":303},{"nctId":"NCT00579189","phase":"PHASE3","title":"Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-01","conditions":"Acute Otitis Media","enrollment":776},{"nctId":"NCT00312338","phase":"PHASE4","title":"Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-06","conditions":"Bacterial Conjunctivitis","enrollment":137},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Cataract Extraction","enrollment":105},{"nctId":"NCT00905762","phase":"PHASE1","title":"Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-03","conditions":"Healthy","enrollment":119},{"nctId":"NCT01455233","phase":"PHASE4","title":"2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery","status":"COMPLETED","sponsor":"Ophthalmology Consultants, Ltd.","startDate":"2010-09","conditions":"Corneal Health, Cataract Surgery","enrollment":60},{"nctId":"NCT00564447","phase":"PHASE4","title":"Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections","enrollment":48},{"nctId":"NCT00764582","phase":"PHASE4","title":"Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery","status":"TERMINATED","sponsor":"Santen Inc.","startDate":"2008-09","conditions":"Corneal Transplantation","enrollment":60},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00630019","phase":"PHASE4","title":"Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-02","conditions":"Cataract","enrollment":96},{"nctId":"NCT00569881","phase":"","title":"Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK","status":"COMPLETED","sponsor":"Donnenfeld, Eric, M.D.","startDate":"2007-01","conditions":"Corneal Epithelial Wound Healing","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":485,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Moxifloxacin (Topical)","genericName":"Moxifloxacin (Topical)","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Bacterial conjunctivitis, Bacterial corneal ulcer, Post-operative ocular infection prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}